Reviewing Legend Biotech (NASDAQ:LEGN) & Bicycle Therapeutics (NASDAQ:BCYC)

Legend Biotech (NASDAQ:LEGN) and Bicycle Therapeutics (NASDAQ:BCYC) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, profitability and earnings.

Earnings and Valuation

This table compares Legend Biotech and Bicycle Therapeutics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Legend Biotech $75.68 million 83.66 -$303.48 million ($0.94) -50.64
Bicycle Therapeutics $10.39 million 80.70 -$51.01 million ($2.66) -13.09

Bicycle Therapeutics has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Legend Biotech and Bicycle Therapeutics, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Legend Biotech 0 0 4 0 3.00
Bicycle Therapeutics 0 0 6 0 3.00

Legend Biotech currently has a consensus target price of $50.67, suggesting a potential upside of 6.44%. Bicycle Therapeutics has a consensus target price of $46.00, suggesting a potential upside of 32.11%. Given Bicycle Therapeutics’ higher possible upside, analysts plainly believe Bicycle Therapeutics is more favorable than Legend Biotech.

Insider & Institutional Ownership

19.8% of Legend Biotech shares are held by institutional investors. Comparatively, 47.5% of Bicycle Therapeutics shares are held by institutional investors. 17.9% of Bicycle Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.


This table compares Legend Biotech and Bicycle Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Legend Biotech -437.14% -85.12% -36.93%
Bicycle Therapeutics -504.81% -53.45% -33.18%


Bicycle Therapeutics beats Legend Biotech on 7 of the 11 factors compared between the two stocks.

About Legend Biotech

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in North America and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in relapsed and refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates targeting various cancers, including non-hodgkins lymphoma (NHL), acute myeloid leukemia, and T cell lymphoma. In addition, it is developing allogeneic CAR-T product candidates targeting CD20 for the treatment of NHL and targeting B-cell maturation antigen for the treatment of MM, which are currently in an investigator-initiated Phase 1 clinical trial in China. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with's FREE daily email newsletter.